Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

In a retrospective, observational study, researchers used real-world data to evaluate treatment patterns and outcomes in patients with HR+ HER2- breast cancer who were treated with chemotherapy after disease resistance to endocrine therapy plus CDK4/6 inhibitors. They found that chemotherapy provides relatively limited survival benefit among this patient population, and that this benefit decreases with each additional chemotherapy line. The researchers concluded that these data highlight the need for improved treatment options for this patient population. The researchers noted that although antibody–drug conjugates have recently been approved in this setting, it is too early to assess real-world data on their effects.